TrialBreast cancer research and treatment2023

Plasma ESR1 mutations and outcome to first-line paclitaxel and bevacizumab in patients with advanced ER-positive/HER2-negative breast cancer.

M K Bos et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.